Technical White Paper: SOMAscan™ Proteomic Assay
13 August 2013
The SOMAscan assay is a powerful, highly multiplexed platform for discovering novel biomarkers during drug discovery, pre-clinical and clinical drug development, and for the development of clinical diagnostics, across a wide range of clinically important diseases. This white paper demonstrates how SomaLogic’s SOMAscan technology provides significant advantages in sample size, cost, time, multiplexing capability, dynamic range, and flexibility of readout over many alternate protein biomarker platforms. It has been used successfully for many sample types and is optimized for human analytes. It scales easily to progress from biomarker discovery to focused products without the need for new assay development. This technology has can be readily employed as a valuable tool from basic research to drug discovery to diagnostic development.